Jaguar health provides company updates and reports 2022 first quarter financials

Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over mytesi net revenue in the first quarter of 2021 core initiatives: ontarget phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) adding international sites, targeting completion of enrollment 1h 2023 targeted completion in 2022 & 2023 of investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders, supporting the potential for expanded patient access through programs in europe in 2023 ongoing launch of canalevia®-ca1, which is now commercially available for treatment of chemotherapy-induced diarrhea (cid) in dogs reminder: jaguar to host investor webcast tuesday, may 10th at 8:30 a.m. eastern regarding first quarter 2022 financials and company updates; click here to register for webcast san francisco, ca / accesswire / may 10, 2022 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today provided company updates and reported consolidated first quarter 2022 financial results.
JAGX Ratings Summary
JAGX Quant Ranking